Yifan Zhao*†1, Longxiao Wang*1, Qianyi Huang*‡, Youqin Jiang*, Jingdong Wang*, Liyuan Zhang‡§, Ye Tian‡§, Hongying Yang*§
Oncology Research, Vol.24, No.1, pp. 1-7, 2016, DOI:10.3727/096504016X14570992647087
Abstract Although medically inoperable patients with stage I non-small cell lung cancer cells (NSCLC) are often treated with
stereotactic body radiation therapy, its efficacy can be compromised due to poor radiosensitivity of cancer cells.
Inhibition of transforming growth factor-β1 (TGF-β1) using LY364947 and LY2109761 has been demonstrated to
radiosensitize cancer cells such as breast cancer, glioblastoma, and lung cancer. Our previous results have demonstrated that another potent and selective inhibitor of TGF-β1 receptor kinases, SB431542, could radiosensitize H460
cells both in vitro and in vivo. In the present study, we investigated whether SB431542 could radiosensitize other… More >